<DOC>
	<DOC>NCT01127633</DOC>
	<brief_summary>This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).</brief_summary>
	<brief_title>Continued Safety Monitoring of Solanezumab in Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease Has completed participation in solanezumab Study LZAM or Study LZAN through 80 weeks Must continue to have a reliable caregiver who is in frequent contact with the patient for the entire study Must have good vein access to administer infusions Agrees not to participate in studies of any other investigational compounds for the duration of their participation in Study LZAO Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or offlabel use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study Meets LZAM or LZAN discontinuation criteria at the end of treatment in LZAM or LZAN study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>